Cargando…

Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China

Although the potent antibacterial ability of radezolid against Staphylococcus aureus has been widely reported worldwide, its antibacterial and anti-biofilm activity against the S. aureus clinical isolates from China remains elusive. In this study, the minimum inhibitory concentration (MIC) of radezo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Cong, Xiong, Yanpeng, Bao, Chai, Wei, Ying, Wen, Zewen, Cao, Xinyi, Yu, Zhijian, Deng, Xiangbing, Li, Guiqiu, Deng, Qiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169660/
https://www.ncbi.nlm.nih.gov/pubmed/37180277
http://dx.doi.org/10.3389/fmicb.2023.1131178
_version_ 1785039087616393216
author Wang, Cong
Xiong, Yanpeng
Bao, Chai
Wei, Ying
Wen, Zewen
Cao, Xinyi
Yu, Zhijian
Deng, Xiangbing
Li, Guiqiu
Deng, Qiwen
author_facet Wang, Cong
Xiong, Yanpeng
Bao, Chai
Wei, Ying
Wen, Zewen
Cao, Xinyi
Yu, Zhijian
Deng, Xiangbing
Li, Guiqiu
Deng, Qiwen
author_sort Wang, Cong
collection PubMed
description Although the potent antibacterial ability of radezolid against Staphylococcus aureus has been widely reported worldwide, its antibacterial and anti-biofilm activity against the S. aureus clinical isolates from China remains elusive. In this study, the minimum inhibitory concentration (MIC) of radezolid was determined in S. aureus clinical isolates from China using the agar dilution method, and the relationship between radezolid susceptibility and ST distribution was also investigated. The anti-biofilm activity of radezolid against S. aureus was determined by a crystal violet assay and compared with that of linezolid and contezolid. The quantitative proteomics of S. aureus treated with radezolid was analyzed, and the genetic mutations in radezolid-induced resistant S. aureus were determined by whole-genome sequencing. The dynamic changes in transcriptional expression levels of several biofilm-related genes were analyzed by quantitative RT-PCR. Our data showed that radezolid MIC ranged from ≤0.125 to 0.5 mg/L, which was almost 1/4 × MIC of linezolid against S. aureus, indicating the greater antibacterial activity of radezolid than linezolid. The S. aureus clinical isolates with radezolid MICs of 0.5 mg/L were most widely distributed in ST239 of MRSA and ST7 of MSSA. Moreover, the more robust anti-biofilm activity of radezolid with subinhibitory concentrations (1/8 × MIC and 1/16 × MIC) was demonstrated against S. aureus when compared with that of contezolid and linezolid. Genetic mutations were found in glmS, 23S rRNA, and DUF1542 domain-containing protein in radezolid-induced resistant S. aureus selected by in vitro induction of drug exposure. Quantitative proteomic analysis of S. aureus indicated that the global expression of some biofilm-related and virulence-related proteins was downregulated. Quantitative RT-PCR further confirmed that the expressions of some downregulated biofilm-related proteins, including sdrD, carA, sraP, hlgC, sasG, spa, sspP, fnbA, and oatA, were decreased after 12 h and 24 h of exposure to radezolid. Conclusively, radezolid shows robust antibacterial and anti-biofilm activity against S. aureus clinical isolates from China when compared with contezolid and linezolid.
format Online
Article
Text
id pubmed-10169660
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101696602023-05-11 Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China Wang, Cong Xiong, Yanpeng Bao, Chai Wei, Ying Wen, Zewen Cao, Xinyi Yu, Zhijian Deng, Xiangbing Li, Guiqiu Deng, Qiwen Front Microbiol Microbiology Although the potent antibacterial ability of radezolid against Staphylococcus aureus has been widely reported worldwide, its antibacterial and anti-biofilm activity against the S. aureus clinical isolates from China remains elusive. In this study, the minimum inhibitory concentration (MIC) of radezolid was determined in S. aureus clinical isolates from China using the agar dilution method, and the relationship between radezolid susceptibility and ST distribution was also investigated. The anti-biofilm activity of radezolid against S. aureus was determined by a crystal violet assay and compared with that of linezolid and contezolid. The quantitative proteomics of S. aureus treated with radezolid was analyzed, and the genetic mutations in radezolid-induced resistant S. aureus were determined by whole-genome sequencing. The dynamic changes in transcriptional expression levels of several biofilm-related genes were analyzed by quantitative RT-PCR. Our data showed that radezolid MIC ranged from ≤0.125 to 0.5 mg/L, which was almost 1/4 × MIC of linezolid against S. aureus, indicating the greater antibacterial activity of radezolid than linezolid. The S. aureus clinical isolates with radezolid MICs of 0.5 mg/L were most widely distributed in ST239 of MRSA and ST7 of MSSA. Moreover, the more robust anti-biofilm activity of radezolid with subinhibitory concentrations (1/8 × MIC and 1/16 × MIC) was demonstrated against S. aureus when compared with that of contezolid and linezolid. Genetic mutations were found in glmS, 23S rRNA, and DUF1542 domain-containing protein in radezolid-induced resistant S. aureus selected by in vitro induction of drug exposure. Quantitative proteomic analysis of S. aureus indicated that the global expression of some biofilm-related and virulence-related proteins was downregulated. Quantitative RT-PCR further confirmed that the expressions of some downregulated biofilm-related proteins, including sdrD, carA, sraP, hlgC, sasG, spa, sspP, fnbA, and oatA, were decreased after 12 h and 24 h of exposure to radezolid. Conclusively, radezolid shows robust antibacterial and anti-biofilm activity against S. aureus clinical isolates from China when compared with contezolid and linezolid. Frontiers Media S.A. 2023-04-26 /pmc/articles/PMC10169660/ /pubmed/37180277 http://dx.doi.org/10.3389/fmicb.2023.1131178 Text en Copyright © 2023 Wang, Xiong, Bao, Wei, Wen, Cao, Yu, Deng, Li and Deng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Wang, Cong
Xiong, Yanpeng
Bao, Chai
Wei, Ying
Wen, Zewen
Cao, Xinyi
Yu, Zhijian
Deng, Xiangbing
Li, Guiqiu
Deng, Qiwen
Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China
title Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China
title_full Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China
title_fullStr Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China
title_full_unstemmed Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China
title_short Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China
title_sort antibacterial and anti-biofilm activity of radezolid against staphylococcus aureus clinical isolates from china
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169660/
https://www.ncbi.nlm.nih.gov/pubmed/37180277
http://dx.doi.org/10.3389/fmicb.2023.1131178
work_keys_str_mv AT wangcong antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina
AT xiongyanpeng antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina
AT baochai antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina
AT weiying antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina
AT wenzewen antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina
AT caoxinyi antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina
AT yuzhijian antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina
AT dengxiangbing antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina
AT liguiqiu antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina
AT dengqiwen antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina